2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
2seventy bio Inc Ordinary Shares TSVT
News
-
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
Thinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?
Thinking about buying stock in Solidion Technology, Nuvei, 2Seventy Bio, Aeye, or DHC Acquisition?
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
Correction to 2seventy to Sell R&D Pipeline Article
2seventy to Sell R&D Pipeline to Regeneron, Focus on Abecma
Bristol Myers Gets Positive CHMP Opinion for Earlier Abecma Use
Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
2seventy Bio Shares Fall Premarket on Abecma Expansion Delay
FDA Advisory Panel to Meet on Earlier Use of Abecma From Bristol, 2seventy